Related Experiment Video

Updated: Aug 8, 2026

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

Elisa Greggio1, Shushant Jain, Ann Kingsbury

  • 1Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892-3707, USA.

Neurobiology of Disease
|June 6, 2006
PubMed

Insights

Mutations in the LRRK2 gene cause Parkinson's disease. Inhibiting dardarin kinase activity reduces inclusion body formation and cell death, suggesting kinase inhibitors may treat Parkinson's disease.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Mutations in the Leucine-Rich Repeat Kinase 2 (LRRK2) gene are a primary cause of inherited Parkinson's disease (PD).
  • Dardarin, the protein encoded by LRRK2, is implicated in PD pathogenesis, but the role of its kinase activity in disease mechanisms remains unclear.
  • Pathogenic LRRK2 mutations lead to distinct cellular phenotypes, including protein aggregation and neuronal cell death.

Purpose of the Study:

  • To investigate the role of dardarin kinase activity in the cellular phenotypes associated with LRRK2 mutations in Parkinson's disease.
  • To determine if modulating kinase activity can mitigate the damaging effects of mutant dardarin.
  • To assess the therapeutic potential of kinase inhibitors for LRRK2-related and sporadic Parkinson's disease.

Main Methods:

  • Expression of wild-type and mutant dardarin in neuronal cell lines.
  • Generation of a 'kinase-dead' LRRK2 mutant by altering the kinase domain.
  • Assessment of inclusion body formation and cell viability following expression of different LRRK2 variants.
  • Immunohistochemical analysis of dardarin expression in human midbrain neurons and Lewy bodies.

Main Results:

  • Pathogenic LRRK2 mutations significantly increase the propensity of dardarin to form inclusion bodies.
  • Expression of mutant dardarin induces neuronal cell death.
  • Conversion of the kinase domain to a 'kinase-dead' form abrogates inclusion body formation and markedly delays cell death.
  • Dardarin protein is present in human midbrain neurons, with C-terminal epitopes detected in some Lewy bodies.

Conclusions:

  • Dardarin kinase activity is crucial for the development of cellular pathologies observed in LRRK2-related Parkinson's disease.
  • Targeting LRRK2 kinase activity with inhibitors presents a promising therapeutic strategy for LRRK2 mutations.
  • Kinase inhibitors may also hold potential for treating sporadic Parkinson's disease, given the role of LRRK2 in neuronal health.

More Related Videos

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...